Principles of metered-dose inhaler design

Respiratory Care

Volumn 50, Issue 9, 2005, Pages 1177-1188

  Newman, Stephen P ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Aerosol; Asthma; Chronic obstructive pulmonary disease; Drug delivery; MDI; Metered dose inhaler; Spacer

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; FLUTICASONE; FORMOTEROL; PIRBUTEROL; PROPELLANT; SALBUTAMOL;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONTAINER; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; METERED DOSE INHALER; VAPOR PRESSURE; BREATHING MECHANICS; CHEMISTRY; DRUG EFFECT; EQUIPMENT DESIGN; INHALATION SPACER; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; REVIEW; COMPUTER AIDED DESIGN; INHALER;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; CHEMISTRY, PHARMACEUTICAL; EQUIPMENT DESIGN; HUMANS; INHALATION SPACERS; METERED DOSE INHALERS; RESPIRATORY MECHANICS;

EID: 33846636423     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. Thiel CG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996:115-123.
2. Brown BAS. Dispelling the myths of MDIs. Drug Delivery Technology 2002;2(7):1-7.
3. Tansey IP. The challenges in the development of metered-dose inhalation aerosols using ozone-friendly propellants. Proceedings of the First European Pharm Tech Conference, Dusseldorf; 1993:182-187.
4. Polli GP, Grim WM, Bacher FA, Yunker MH. Influence of formulation on aerosol particle size. J Pharm Sci 1969;58(4):484-486.
5. Smyth HD. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Revs 2003;55(7):807-828.
6. Noakes T. Medical aerosol propellants. J Fluorine Chem 2002;118(1-2):35-45.
7. Molina MJ, Rowlands FS. Stratospheric sink for chlorofluoromethanes: chlorine atomcatalysed destruction of ozone. Nature 1974;249: 1810-1812.
8. Partridge MR, Woodcock AA. Propellants. In: Bisgaard H, O'Callaghan C, Smaldone GC, editors. Drug delivery to the lung. New York: Marcel Dekker; 2002:371-388.
9. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers: into the new millenium. Int J Pharm 2000;201(1):89-107.
10. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999;186(1):13-20.
11. Smith IJ. The challenge of reformulation. J Aerosol Med 1995;8 Suppl 1:S19-S27.
12. Food and Drug Administration. Chlorofluorocarbon propellants in self-propelled containers; addition to list of essential uses. Federal Register 1993;58:6086-6088.
13. Hallworth GW. The formulation and evaluation of pressurised metered dose inhalers. In: Ganderton D, Jones T, editors. Drug delivery to the respiratory tract. Chichester, United Kingdom: Ellis Horwood; 1987:87-118.
14. Lewis DA, Ganderton D, Meakin BJ, Brambilla G. Theory and practice with solution systems. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors. Respiratory drug delivery IX. River Grove, Illinois: Davis Healthcare International; 2004:109-115.
15. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94 Suppl B:S3-S9.
16. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12(6):1346-1353.
17. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with anew propellant. J Allergy Clin Immunol 1999;104(6): 1215-1222.
18. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a Chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999;12(3):151-160.
19. Berg E. In vitro properties of pressurised metered dose inhalers with and without spacer devices. J Aerosol Med 1995;8 Suppl 3:S3-S11.
20. Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, et al. In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler. Pharm Res 2002;19(3):258-264.
21. Gupta P, Adjei A. Therapeutic inhalation aerosols. In: Adjei A, Gupta P, editors. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker; 1997:185-229.
22. Stein SW, Forsyth BR, Stefely JS, Christensen JD, Alband TD, Jinks PA. Expanding the dosing range of metered dose inhalers through formulation and hardware optimisation. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors. Respiratory drug delivery IX. River Grove, Illinois: Davis Healthcare International; 2004:125-133.
23. O'Callaghan C, Wright P. The metered-dose inhaler. In: Bisgaard H, O'Callaghan C, Smaldone GC, editors. Drug delivery to the lung. New York: Marcel Dekker; 2002:337-370.
24. Schultz RK, Dupont RL, Ledoux KA. Issues surrounding metered dose valve technology: past, present and future perspectives. In: Byron PR, Dalby RN, Farr SJ, editors. Respiratory drug delivery IV. Buffalo Grove, Illinois: Interpharm Press; 1994:211-219.
25. Cyr TD, Graham SJ, Lee KY, Lovering EG. Low first-spray drug content in albuterol metered dose inhalers. Pharm Res 1991;8(5): 658-660.
26. Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluorocarbon transition-valve performance. J Allergy Clin Immunol 1999;104(6):S230-S235.
27. Newman S, Pitcairn G, Steed K, Harrison A, Nagel J. Deposition of fenoterol from pressurized metered dose inhalers containing hydrofluoroalkanes. J Allergy Clin Immunol 1999;104(6):S253-S257.
28. Warren SJ, Farr SJ. Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int J Pharm 1995;124(2):195-203.
29. Clark AR. MDIs: physics of aerosol formation. J Aerosol Med 1996; 9(Suppl 1):S19-S26.
30. Versteeg HK, Hargrave GK, Wigley G. The physics of aerosol formulation by pMDI: an update. Proceedings of Drug Delivery to the Lungs XIII. Portishead: The Aerosol Society; 2002:60-66.
31. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999;186(1):3-12.
32. Rance RW. Studies of the factors controlling the action of hair sprays. J Soc Cosmet Chem 1974;25:545-561.
33. Davies RJ, Lewis DA, Ganderton D, Meakin BJ, Brambilla G, Murphy SD, Nicholls TR. Velocity profiling of a new HFA budesonide pMDI. In: Dalby RN, Byron PR, Peart J, Farr SF, editors. Respiratory drug delivery VIII. Raleigh: Davis Horwood; 2002:759-762.
34. Rubin BK, Durotoye L. How do patients determine that their metered-dose inhaler is empty? Chest 2004;126(4):1134-1137.
35. Food and Drug Administration. Guidance for industry: integration of dose-counting mechanisms into MDI drug products: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001. http://www. fda.gov/cder/guidance/index.htm. Accessed June 21, 2005.
36. Brambilla G, Ganderton D, Garzia R, Lewis D, Meakin B, Ventura P. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999;186(1):53-61.
37. Crompton GK. Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis 1982;63(Supplement 119):57-65.
38. Newman SP, Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991;46(10):712-716.
39. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19(2): 246-251.
40. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000;94(5):496-500.
41. Crompton GK. Breath-activated aerosol. Br Med J 1971;2(762):652-653.
42. Bacon RJ, McDermott I, Bell J. A new breath operated actuator. In: Dalby RN, Byron PR, Peart J, Farr SF, editors. Respiratory drug delivery VIII. Raleigh: Davis Horwood; 2002:403-406.
43. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled metered dose inhaler. Thorax 1995;50(6):639-644.
44. Howlett D. Devices to assist patient co-ordination with pMDIs: a review. Proceedings of Drug Delivery to the Lungs IX. Portishead: The Aerosol Society; 1998:184-187.
45. Zhang FL, Genova PA, Tanguay JF, Cronin J, Sexton F, Cutie AJ, Jewett W, Adjei AL. The breath coordinated inhaler (BCI): a new pulmonary drug delivery device for pressurized metered dose inhalers. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Raleigh: Serentec Press; 2000:323-326.
46. Byron PR, Dalby RN, Hickey AJ. Optimized inhalation aerosols. I. The effects of spherical baffle size and position upon the output characteristics of several pressurized non-aqueous suspension formulations. Pharm Res 1989;6(3):225-229.
47. Newman SP, Steed KP, Hooper G, Jones JI, Upchurch FC. Improved targeting of beclomethasone dipropionate (250 micrograms metered dose inhaler) to the lungs of asthmatics with the Spacehaler. Respir Med 1999;93(6):424-431.
48. Mohsen N. pMDI aerosol momentum manipulation and biotargeted delivery. In: Dalby RN, Byron PR, Peart J, Farr SF, editors. Respiratory drug delivery VIII. Raleigh: Davis Horwood; 2002:593-597.
49. Steckel H, Müller BW. Metered dose inhaler add-on devices: an in vitro evaluation of the BronchoAir inhaler and several spacer devices. J Aerosol Med 1998;11(3):133-142.
50. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9(1):55-70.
51. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinetics 2004;43(6):349-360.
52. Franklin W, Lowell F, Michelson AL, Schiller I. Aerosolized steroids in bronchial asthma. J Allergy 1958;29(3):214-221.
53. Hardy J, Jasuja A, Frier M, Perkins A. A small volume spacer for use with a breath-operated pressurised metered dose inhaler. Int J Pharm 1996;142(2):129-133.
54. Newman SP, Clark AR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an "open" spacer. Thorax 1989;44(9):706-710.
55. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127(1):335-371.
56. Bisgaard H, Anhoj J, Wildhaber JH. Spacer devices. In: Bisgaard H, O'Callaghan C, Smaldone GC, editors. Drug delivery to the lung. New York: Marcel Dekker; 2002:389-420.
57. Kenyon CJ, Thorsson L, Borgström L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 1998;11(3):606-610.
58. Wildhaber JH, Devadason SG, Eber E, Hayden MJ, Everard ML, Summers QA, Le Souëf PN. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996;51(10): 985-988.
59. Mitchell J, Morton R, Schmidt J, Snyder S, Doyle C, Nagel M. Overcoming electrostatic charge retention in a new valved holding chamber (VHC): in vitro performance comparison with current devices. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, editors, Respiratory drug delivery IX. River Grove, Illinois: Davis Healthcare International, 2004, 705-707.
60. Esposito-Festen JE, Ates B, van Vliet FJ, Verbraak AF, de Jongste JC, Tiddens HA. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med 2004;17(1):1-6.
61. Newman SP, Woodman G, Clarke SW, Sackner MA. Effect of InspirEase on the deposition of metered dose aerosols in the human respiratory tract. Chest 1986;89(4):551-556.
62. Dolovich MB. In vitro measurements of delivery of medications from MDIs and spacer devices. J Aerosol Med 1996;9 Supplement 1:S49-S58.
63. Barry PW, O'Callaghan C. The optimum size and shape of spacer devices for inhalational therapy. J Aerosol Med 1995;8:303-305.
64. Zak M, Madsen J, Berg E, Bulow J, Bisgaard H. A mathematical model of aerosol holding chambers. J Aerosol Med 1999;12(3):187-196.
65. Barry PW, O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996;51(8):835-840.
66. Mitchell JP, Nagel MW, Rau JL. Performance of large-volume versus small volume holding chambers with chlorofluorocarbon-albuterol and hydrofluoroalkane-albuterol sulphate. Respir Care 1999; 44(1):38-44.
67. Verbanck S, Vervaet C, Schuermans D, Vincken W. Aerosol profile extracted from spacers as a determinant of actual dose. Pharm Res 2004;21:2213-2218.